| Drug General Information |
| Drug ID |
D0U1CL
|
| Former ID |
DIB013087
|
| Drug Name |
PGX-200097
|
| Synonyms |
COMT/dopamine D2 receptor inhibitors (schizophrenia), Psychiatric Genomics; Catechol-O-methyltransferase/dopamine D2 receptor inhibitors (schizophrenia), Psychiatric Genomics
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Preclinical |
[1]
|
|---|
| Company |
Psychiatric Genomics Inc
|
| Target and Pathway |
| Target(s) |
Catechol-O-methyl-transferase |
Target Info |
Inhibitor |
[2]
|
|---|
| D(2) dopamine receptor |
Target Info |
Inhibitor |
[2]
|
|
BioCyc Pathway
|
L-dopa degradation
|
|
Dopamine degradation
|
|
Noradrenaline and adrenaline degradation
|
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
|
Tyrosine metabolism
|
|
Metabolic pathways
|
|
Dopaminergic synapsehsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
|
Dopamine receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
PathWhiz Pathway
|
Tyrosine Metabolism
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Methylation Pathways
|
|
Metapathway biotransformation
|
|
Estrogen metabolism
|
|
Biogenic Amine Synthesis
|
|
Dopamine metabolism
|
|
Phase II conjugation
|
|
Neurotransmitter Clearance In The Synaptic CleftWP666:Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024498) |
|---|
| REF 2 | Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010 Sep;122(1-3):1-23. |
|---|
